FrancophonIA/ELRC3.0 huggingface dataset:
English: Similarly, administration of 400 mg posaconazole with esomeprazole (40 mg daily) decreased mean Cmax and AUC by 46 % and 32 %, respectively, compared to dosing with 400 mg posaconazole alone.
Maltese: Bl-istess mod, l-għotja ta' 400 mg posaconazole ma' esomeprazole (40 mg kuljum) naqset il-medja tasCmax u l-AUC b'46 % u 32 % rispettivament, meta imqabbel ma dożaġġi b'400 mg posaconazole waħdu.
English: Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), efavirenz and cimetidine
Maltese: Antibatteriċi ta' rifamycin (rifampicin, rifabutin), ċerti mediċini kontra l-aċċessjonijiet (phenytoin,
English: In Study 316, overall mortality was similar (POS, 25 %; FLU, 28 %); however, the proportion of IFIrelated deaths was significantly lower in the POS group (4/301) compared with the FLU group (12/299; P= 0.0413).
Maltese: FLU, 28 %); iżda l-proporzjon ta' mwiet relatati ma' IFI kienet aktar baxxa b'mod sinifikanti fil-grupp ta' POS (4/301) meta mqabbla mal- grupp ta' FLU (12/299; P= 0.
English: c: In 1899, this was the period from randomization to 100 days post-randomization; in 316 it was the period from the baseline day to 111 days post-baseline.
Maltese: F'1899 dan kien il-perijodu minn meta kienu randomized sa 100 jum wara li kienu randomized; fi 316 dan kien il- perijodu mil-jum tal-linja bażi għal 111-il jum wara l-linja bażi.
English: Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1st line therapy
Maltese: Infezzjonijiet fungali invażivi refrattarji (IFI)/pazjenti b'IFI li ma jifilħux għat-terapija talewwel għażla
English: The active substance is posaconazole.
Maltese: Is-sustanza attiva hija posaconazole.
English: Currently available data are described in sections 5.1 and 5.2, but no recommendation on a posology can be made.
Maltese: Dejta disponibbli hi deskritta fis-sezzjonijiet 5.1 u 5.2 imma l-ebda rakkomandazzjoni dwar il pożoloġija ma tista' tingħata.
English: Posaconazole tablets are the preferred formulation to optimize plasma concentrations and generally provide higher plasma drug exposures than posaconazole oral suspension.
Maltese: Posaconazole pilloli huma l-formulazzjoni preferuta sabiex jiġu ottimizzati l- konċentrazzjoni fil-plasma u ġeneralment jipprovdu esponimenti tal mediċina fil-plasma li huma ogħla minn posaconazole suspensjoni orali.
English: In another study in healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to 7.6-fold), respectively.
Maltese: Fi studju ieħor b'voluntiera b'saħħithom, l-għotja ta' dożi ripetuti ta' posaconazole suspensjoni orali (200 mg darbtejn kuljum għal 7 ijiem) żdied is-Cmax u l-AUC ta' midazolam mogħti ġol-vina (0.4 mg doża waħda) b'medja ta'1.3 u 4.6-il darba (medda 1.7 sa 6.4-il darba), rispettivament;
English: No effects on electrocardiograms, including QT and QTc intervals, were seen in a repeat dose safety pharmacology study in monkeys at systemic exposures 4.6-fold greater than the concentrations obtained at therapeutic doses in humans.
Maltese: Ma dehrux bidliet fl-elettrokardjogrammi, inklużi l-intervalli QT u QTc, fi studju farmakoloġiku dwar is-sigurtà b'dożi ripetuti f'xadini b'esponimenti sistemiċi 4.6-il darba ogħla millkonċentrazzjonijiet li jinkisbu b'dożi terapewtiċi fil-bnedmin.
English: Pharmacokinetic modeling with an oral tablet formulation suggests that patients weighing greater than 120 kg may have lower posaconazole exposure.
Maltese: Immudellar farmakokinetiku b'formulazzjoni ta' pillola orali jissuġġerixxi li pazjenti li jiżnu aktar minn 120 kg jista' jkollhom esponiment aktar baxx għal posaconazole.
English: Posaconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism.
Maltese: Posaconzole jista' jżid il-konċentrazzjoni fil-plażma ta' alkalojdi ergot (ergotamine u dihydroergotamine), li jista' jwassal għal ergotiżmu.
English: This medicine contains less than 1 mmol sodium (23 mg) per 5 mL of suspension, that is to say essentially ‘sodium-free'.
Maltese: Din il-mediċina fiha inqas minn 1 mmol sodium (23 mg ) għal kull 5 mL ta' suspensjoni, jiġifieri hija essenzjalment “mingħajr sodium”.
English: See Table 5 and 6 for results from both studies.
Maltese: Ara Tabella 5 u 6 għar-riżultati miż-żewġ studji.
English: There are currently insufficient data to set clinical breakpoints for Aspergillus spp.
Maltese: Fil-preżent ma hemmx dejta biżżejjed sabiex jiġu stabbiliti breakpoints kliniċi għal Aspergillus spp.
English: Repeat dose administration of posaconazole oral suspension (400 mg twice daily for 16 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 6.7-fold and 8.9-fold (range 3.1 to 17.5-fold), respectively, in healthy subjects.
Maltese: L-għoti ta' dożi ripetuti ta' posaconazole suspensjoni orali (400 mg darbtejn kuljum għal 16-il jum) żiedet is-Cmax u l-AUC ta'sirolimus (2 mg doża waħda) b'medja ta' 6.7-il darba u 8.9-il darba (medda 3.1 sa 17.5-il darba), rispettivament, f'voluntiera b'saħħithom.
English: A key secondary endpoint was the incidence of proven/probable IFIs during the on-treatment period (first dose to last dose of study medicinal product + 7 days).
Maltese: Endpoint essenzjali sekondarju kien l-inċidenza ta' IFI's li probabbli/ġew pruvati li seħħew waqt il-perijodu tal- kura (l-ewwel doża sa l-aħħar doża tal-prodott mediċinali li qed jiġi studjat+ 7 ijiem).
English: Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required.
Maltese: Wara li tingħata doża waħda ta' posaconazole suspensjoni orali, ma kienx hemm effett minn insuffiċjenza renali ħafifa u moderata (n=18, Cl cr ≥ 20 mL/min/1.73 m2) fuq il-farmakokinetiċi ta' posaconazole, għalhekk m'hemmx bżonn tibdil fid-doża.
English: d: All randomized e: All treated
Maltese: d: Kollha randomized e:
English: Posaconazole was not genotoxic in in vitro and in vivo studies.
Maltese: Posaconazole ma kienx ġenotossiku fi studji in vitro u in vivo.
English: A. niger
Maltese: L-Ungerija
English: In a study in healthy volunteers posaconazole oral suspension (200 mg once daily for 10 days) increased the exposure (AUC) of intravenous midazolam (0.05 mg/kg) by 83 %.
Maltese: 10 ijiem) żied l-esponiment (AUC) ta' midazolam mogħti ġol-vina (0.05 mg/kg) bi 83 %.
English: After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose).
Maltese: Wara li jingħata 14C-posaconazole, ir-radjuattività inġabret fil-parti l-kbira mill-ippurgar (77 % tad- doża radjutikkettata) bl-akbar komponent ikun il-mediċina oriġinali (66 % tad-doża radjutikkettata).
English: Posaconazole AHCL contains approximately 1.75g of glucose per 5mLof suspension.
Maltese: Posaconazole AHCL fih il-glucose Posaconazole AHCL fih madwar 1.75g ta' glucose għal kull 5mL ta' suspensjoni.
English: In Study 1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS 49/304 (16 %) vs. FLU/ITZ 67/298 (22 %) p= 0.048].
Maltese: Fi studju 1899, deher tnaqqis sinifikanti fil-kawżi kollha ta' mwiet favur posaconazole [POS 49/304 (16 %) vs.
English: 9 of 11 patients were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 268 days and up to 377 days.
Maltese: 9 mill-11-il pazjent li kienu kkurati b'suċċess b'posaconazole suspensjoni orali 800 mg/jum f'dożi maqsumin għal medjan ta' 268 jum u sa 377 jum.
English: Both doses of posaconazole increased Cmax and AUC of oral midazolam (2 mg single oral dose) by 2.2 and 4.5-fold, respectively.
Maltese: midazolam mill-ħalq (2 mg doża waħda mill- ħalq) b'2.2 u 4.5-il darba, rispettivament.
English: Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the
Maltese: fosamprenavir (700 mg darbtejn kuljum x 10 ijiem) naqqas is-Cmax u l-AUC ta' posaconazole suspensjoni orali (200 mg darba kuljum fl-ewwel jum, 200 mg darbtejn kuljum fit-tieni jum, imbagħad 400 mg darbtejn kuljum x
English: 11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 124 days and up to 212 days.
Maltese: 11 minn 24 pazjent li wrew li probabbli kellhom fusarjożi kienu ikkurati b'suċċess b'posaconazole suspensjoni orali 800 mg/jum b'dożi maqsumin għal medjan ta' 124 jum u sa 212- jum.
English: Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4).
Maltese: L-għoti fl istess ħin ta' antifungali azole, inkluż posaconazole b'vincristine ġie assoċjat ma' reazzjonijiet avversi serji (ara sezzjoni 4.4).
English: high or low blood pressure - low blood pressure - inflammation of the pancreas (pancreatitis) - this may cause severe stomach pain - oxygen supply to the spleen is interrupted (splenic infarction) - this may cause severe stomach pain - severe kidney problems - signs include passing more or less urine, that is a different colour than usual - high blood levels of creatinine - shown in blood tests - cough, hiccups - nose bleeds - severe sharp chest pain when breathing in (pleurritic pain) - swelling of lymph glands (lymphadenopathy) - reduced feeling of sensitivity especially on the skin - tremor - high or low blood sugar levels - blurred vision, sensitivity to light - hair loss (alopecia) - mouth ulcers - shivering, feeling generally unwell - pain, back or neck pain, pain in arms or legs - water retention (oedema) - menstrual problems (abnormal vaginal bleeding) - inability to sleep (insomnia) - being completely or partially unable to talk - swelling of the mouth - abnormal dreams, or difficulty sleeping - problems with co-ordination or balance - mucosal inflammation - stuffy nose - difficulty breathing - chest discomfort - feeling bloated - mild to severe nausea, vomiting, cramps and diarrhoea, usually caused by a virus, stomach pain - belching - feeling jittery
Maltese: ħsara fin-nervituri (newropatija) ritmu tal-qalb abnormali - jidher fuq traċċar tal-qalb (ECG), palpitazzjonijiet, taħbita tal-qalb bil-mod jew mgħaġġla, pressjoni tad-demm għolja jew baxxa pressjoni tad-demm baxxa infjammazzjoni tal-frixa (pankreatite) - dan jista' jikkawża wġigħ sever fl-istonku interruzzjoni fil-provvista tal-ossiġnu għall-milsa (infart tal-milsa) - dan jista' jikkawża uġigħ qawwi fl-istonku problemi severi fil-kliewi - is-sinjali jinkludu li tgħaddi aktar jew anqas awrina, li tkun ta' kulur differenti mis-soltu livelli għoljin ta' krejatinina fid-demm - murija f'testijiet tad-demm sogħla, sulluzzu fsada mill-imnieħer uġigħ sever qawwi fis-sider meta tieħu n-nifs (uġigħ plewritiku) nefħa tal-glandoli limfatiċi (limfadenopatija) tnaqqis fis-sensazzjoni ta' sensittività speċjalment fuq il-ġilda tregħid livelli għoljin jew baxxi taz-zokkor fid-demm vista mċajpra, sensittività għad-dawl twaqqigħ tax-xagħar (alopeċja) ulċeri fil-ħalq tertir, tħossok ma tiflaħx b'mod ġenerali uġigħ, uġigħ fid-dahar jew fl-għonq, uġigħ fid-dirgħajn jew fir-riġlejn żamma tal-ilma (edima) problemi mestrwali (fsada abnormali mill-vaġina) ma tkunx tista' torqod (insomnja)
English: INFORMATION IN BRAILLE Posaconazole AHCL
Maltese: Mediċini oħra u Posaconazole AHCL
English: Certain medicines may increase the risk of side effects of Posaconazole AHCL by increasing the amount of Posaconazole AHCL in the blood.
Maltese: Ċerti mediċini jistgħu iżidu r-riskju ta' effetti sekondarji ta' Posaconazole AHCL billi jżidu lammont ta' Posaconazole AHCL fid-demm.
English: - a “statin” such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol.
Maltese: • “statin” bħal simvastatin, atorvastatin jew lovastatin li jintużaw għall-kura ta' livelli għoljin tal- kolesterol.
English: Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion, and paralytic ileus.
Maltese: L-għoti fl-istess ħin ta' antifungali azole, inkluż posaconazole b'vincristine ġie assoċjat ma' newrotossiċità u reazzjonijiet avversi serji oħra, inkluż attakki ta' puplesija, newropatija periferali,
English: Sixteen patients 8-17 years of age were treated with posaconazole oral suspension 800 mg/day in a study for invasive fungal infections (Study 0041).
Maltese: 800 mg/jum fi studju dwar infezzjonijiet invażivi tal-fungu (Studju 0041).
English: 1st day, 200 mg twice daily on the 2
Maltese: 1,200 mg darbtejn kuljum għal 3 ijiem.
English: which are given with ritonavir) - midazolam, triazolam, alprazolam or other “benzodiazepines” (used as sedatives or muscle relaxants) - diltiazem, verapamil, nifedipine, nisoldipine or other “calcium channel blockers” (used to treat high blood pressure) - digoxin (used to treat heart failure) - Glipizide or other “sulfonylureas” (used to treat high blood sugar).
Maltese: midazolam, triazolam, alprazolam u “benżodijażepini” oħrajn (jintużaw bħala sedattivi jew rilassanti tal-muskoli) diltiazem, verapamil, nifedipine, nisoldipine jew “imblukkaturi tal-kanali ta' calcium”
English: How to take Posaconazole AHCL
Maltese: Posaconazole AHCL
English: These medicines include: - vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer) - ciclosporin (used during or after transplant surgery) - tacrolimus and sirolimus (used during or after transplant surgery) - rifabutin (used to treat certain infections) - medicines used to treat HIV called protease inhibitors (including lopinavir and atazanavir,
Maltese: vincristine, vinblastine u alkalojdi vinka oħrajn (jintużaw għall-kura tal-kanċer) ciclosporin (jintuża meta issir kirurġija ta' trapjant jew wara) tacrolimus u sirolimus (jintużaw meta issir kirurġija ta' trapjant jew wara) rifabutin (jintuża għall-kura ta' ċerti infezzjonijiet) mediċini li jintużaw għall-kura ta' HIV li jissejħu impedituri protease (jinkludu lopinavir u atazanavir, li jingħataw ma' ritonavir)
English: Following co-administration of posaconazole oral suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold), respectively.
Maltese: Wara l-għotja flistess- ħin ta' posaconazole suspensjoni orali (400 mg darbtejn kuljum) ma' atazanavir (300 mg darba kuljum) għal 7 ijiem f'individwi b'saħħithom is-Cmax u l-AUC ta' atazanavir żdied b'medja ta' 2.6-il darba u 3.7-il darba (medda 1.2 sa 26-il darba), rispettivament.
English: ul.
Maltese: L-M
English: No clinically relevant changes in the mean QTc (Fridericia) interval from baseline were observed.
Maltese: Ma dehrux bidliet ta' rilevanza klinika fil-medja tal- intervall tal-QTc (Fridericia) mil-linja bażi.
English: There were fewer breakthrough Aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients.
Maltese: Aspergillus f'pazjenti li ngħataw profilassi b'posaconazole meta mqabbla mal-pazjenti tal kontroll.
English: Renal clearance is a minor elimination pathway, with 14 % of the radiolabelled dose excreted in urine (< 0.2 % of the radiolabelled dose is parent compound).
Maltese: It- tneħħija mill-kliewi hija mezz ta' eliminazzjoni minuri, b'14 % tad-doża radjutikkettata imneħħija mill-awrina (< 0.2 % tad-doża radjutikkettata tkun il-mediċina oriġinali).
English: Oral posaconazole suspension 800 mg/day in divided doses was evaluated for the treatment of invasive aspergillosis in patients with disease refractory to amphotericin B (including liposomal formulations) or itraconazole or in patients who were intolerant of these medicinal products in a noncomparative salvage therapy trial (Study 0041).
Maltese: asperġillożi invażiva f'pazjenti b'mard li kien refrattarju għal amphotericin B (inklużi formulazzjonijiet liposomali) jew itraconazole jew f'pazjenti li kienu intolleranti għal dawn ilprodotti mediċinali fi prova mhux kumparattiva b'terapija ta' salvataġġ (Studju 0041).
English: Dose adjustment of benzodiazepines metabolised by CYP3A4 should be considered (see section 4.5).
Maltese: metaboli ossidattivi (medjati b'CYP450).
English: Following co-administration of posaconazole oral suspension (400 mg twice daily) with atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively.
Maltese: Wara l-għotja fl-istessħin ta' posaconazole suspensjoni orali mill-ħalq (400 mg darbtejn kuljum) ma' azatanavir u ritonavir (300/100 mg darba kuljum) għal 7 ijiem f'individwi b'saħħithom is-Cmax u l-AUC ta' atazanavir żdiedu b'medja ta' 1.5- il darba u 2.5-il darba (medda 0.9 sa 4.1-il darba), rispettivament.
English: Results from clinical studies in prophylaxis of Invasive Fungal Infections Study
Maltese: Riżultati mill-istudji kliniċi fil-profilassi ta' Infezzjonijiet Invażivi bil-Fungu
English: Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88 %) and in the external control group (79 %).
Maltese: Il- parti l-kbira tal-każijiet ta' asperġillożi kienu meqjusa refrattorji għat-terapija li ngħatat qabel kemm fil-grupp ta' posaconazole (88 %) kif ukoll fil-grupp ta' kontroll minn barra (79 %).
English: The critical ratio for subjects with Aspergillus infections was ~200.
Maltese: Il-proporzjon kritiku għall-individwi b'infezzjonijiet ta' Aspergillus kienet ~200.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of oral suspension contains 40 mg of posaconazole.
Maltese: Kull mL ta' suspensjoni orali fih 40 mg ta' posaconazole.
English: Strawberry flavour (containing propylene glycol)
Maltese: halofantrine (użat għall-kura tal-malarja)
English: Unbound concentrations were not determined and it cannot be excluded that there is a larger increase in unbound posaconazole exposure than the observed 60 % increase in total AUC.
Maltese: Il-konċentrazzjonijiet tal-forma ħielsa ma kienux imkejla u ma jistax ikun eskluż li jkun hemm esponiment akbar tal-forma ħielsa ta' posaconazole mis-60 % żieda li dehret fl-AUC totali.
English: For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole AHCL should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm3.
Maltese: Għal pazjenti b'sindromi ta' lewkimja majeloġenuża jew majelodisplastika, profilassi b'Posaconazole AHCL għandha tibda ħafna ġranet qabel ma tkun mistennija li tfeġġ in-newtropenja u titkompla għal 7 ijiem wara li l-għadd tannewtrofili jitla' fuq il- 500 ċellula kull mm3.
English: Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.) of these clearance pathways may increase or decrease posaconazole plasma concentrations, respectively.
Maltese: Għalhekk, impedituri (eż. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, eċċ.) jew indutturi (eż. rifampicin, rifabutin,
English: fluconazole, itraconazole or voriconazole.
Maltese: ITZ = itraconazole;
English: Posaconazole is a potent inhibitor of CYP3A4.
Maltese: Posaconzole huwa impeditur qawwi ta' CYP3A4.
English: Posaconazole AHCL must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5).
Maltese: u magħrufin li jtawlu l-intervall QTc (ara sezzjonijiet 4.3 u 4.5).
English: Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with posaconazole.
Maltese: reazzjonijiet avversi u tossiċità relatata ma' aġenti kontra r- retrovajrus li huma sottostrati ta' CYP3A4 huwa rakkomandat meta jingħataw flimkien ma' posaconazole.
English: Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1): - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.
Maltese: - Fusarjożi f'pazjenti b'mard li hu refrattarju għal amphotericin B jew f'pazjenti intolleranti għal amphotericin B; - Kromoblastomikożi u miċetoma f'pazjenti b'mard li hu refrattarju għal itraconazole jew f'pazjenti intolleranti għal itraconazole;
English: §, electrocardiogram abnormal palpitations, bradycardia, supraventricular extrasystoles, tachycardia
Maltese: sindrome ta' titwil tal-QT§, elettrokardjogramma anormali§, palpitazzjonijiet, bradikardija, sistoli supraventrikulari żejda, takikardija torsade de pointes, mewt f'daqqa, takikardija ventrikulari,
English: You may need to read it again.
Maltese: Għoti ta' dożi ripetuti ta'
English: Therefore, posaconazole may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing posaconazole treatment.
Maltese: posaconazole jista' jżid il-konċentrazzjoni fil-plażma ta' digoxin u l-livelli ta' digoxin għandhom ikunu monitorati meta tinbeda jew titwaqqaf il-kura b'posaconazole.